Search alternatives:
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
-
11141
-
11142
-
11143
-
11144
ESRRA (estrogen related receptor alpha) is a critical regulator of intestinal homeostasis through activation of autophagic flux via gut microbiota
Published 2021“…<p>The orphan nuclear receptor ESRRA (estrogen related receptor alpha) is critical in mitochondrial biogenesis and macroautophagy/autophagy function; however, the roles of ESRRA in intestinal function remain uncharacterized. Herein we identified that ESRRA acts as a key regulator of intestinal homeostasis by amelioration of colonic inflammation through activation of autophagic flux and control of host gut microbiota. …”
-
11145
Data_Sheet_1_Modafinil’s effects on cognition and sleep quality in affectively-stable patients with bipolar disorder: a pilot study.pdf
Published 2023“…</p>Methods<p>Twelve individuals with affectively-stable BD were recruited and randomized to a flexible dose of modafinil (100 to 200 mg/day) or placebo, adjunctive to a therapeutic dose of a mood stabilizer. …”
-
11146
Table 1_Obstetric and perinatal outcomes in pregnancies conceived with donor versus partner sperm: a systematic review and meta-analysis.docx
Published 2025“…Donor sperm was linked to better clinical pregnancy rates (RR 1.27, 95% CI 1.08–1.48) and decreased incidences of biochemical pregnancy (RR 0.85, 95% CI 0.81–0.88), miscarriage (RR 0.91, 95% CI 0.84–1.00), very preterm birth (RR 0.88, 95% CI 0.80–0.96), and very low birth weight (RR 0.89, 95% CI 0.81–0.98) compared with partner sperm. …”
-
11147
Opposite regulation of <i>chd</i> by <i>hairy2a</i> or <i>braEnR</i> depending on the D
Published 2013“…<i>Chd</i> expression decreased in 88% or 100% of dorsalised embryos that were injected with 1 ng of <i>braEnR</i> (<i>braEnR</i>/LiCl; n = 41) or of <i>hairy2a</i> mRNAs (<i>hairy2a</i>/LiCl, n = 23), respectively.…”
-
11148
Table_3_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx
Published 2022“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
-
11149
Table_4_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx
Published 2022“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
-
11150
Table_6_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx
Published 2022“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
-
11151
Table_2_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx
Published 2022“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
-
11152
Table_7_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx
Published 2022“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
-
11153
Table_1_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx
Published 2022“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
-
11154
Table_5_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx
Published 2022“…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
-
11155
-
11156
Table_1_Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study.docx
Published 2023“…The OS rate in SPBC decreased significantly with advanced stage and older age.…”
-
11157
Structure of the IHE model.
Published 2025“…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”
-
11158
Results of base case.
Published 2025“…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”
-
11159
Clinical efficacy data.
Published 2025“…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”
-
11160
Cost-effectiveness acceptable curve.
Published 2025“…Neuropathy decreased by 17.3%. Proteinuria and end-stage renal disease decreased by 25.9% and 17.6% respectively. …”